US recommends ‘pause’ on administration of J&J's COVID-19 vaccine to investigate reports of blood clots
CDC’s Advisory Committee on Immunisation Practices will meet Wednesday to discuss the cases and the FDA has also launched an investigation of the cases
JnJ's vaccine appears to be less prone than Pfizer-BioNTech's and Moderna's, to trigger the kinds of side effects that require monitoring.
Interim data for Biological E's own COVID-19 vaccine, still in clinical trials, is expected later this quarter.
Booster shots will likely be needed, since new virus variants are spreading globally and likely to become the predominant strains.
Experts point out that the global distribution of a vaccine is necessary since none of us is safe until all of us are safe.